18
Innovent Bio
1801.HK·HKEXSuzhou CNFounded 20116,000 employees
Mid CapbiotechPublicOncologyImmunologyMetabolic
Platform: Biologics
Market Cap
$6B
All Drugs
4
Clinical Trials
7
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (1801.HK)
Loading 1801.HK stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 180-6098 | 180-6098 | Phase 1 | 1 | ALK | Heart FailureNMOSD | ||
| Fixalucimab | 180-8060 | Phase 1/2 | 2 | IL-23 | MDD | ||
| Pexanaritide | 180-4203 | Preclinical | 2 | SGLT2 | Breast CaGIST | ||
| 180-3597 | 180-3597 | Preclinical | 2 | SHP2 | Ewing SarcomaLGS |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Innovent Bio trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)